SHANGHAI, May 12, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced today that it has completed an expansion of its materials characterization testing facility in St. Paul, Minnesota.
A new 20,000-square-foot laboratory will offer expanded capacity for existing services, like particle identification and extractable/leachable testing, and add a new service—dynamic light scattering for nanoparticle characterization. These services are required by the FDA for filings of medical devices or biologics. The expansion is designed on a flexible floor plan that allows rapid scale-up of technologies to increase capacities for chemical analysis of medical materials. The new expanded laboratory will begin operation by the end of June.
"WuXi is committed to helping medical device and biologics companies bring their products to market faster," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This facility and WuXi's trained staff will better serve our customers' growing need to quantify the chemical safety of materials used in medical devices and biologics."
For more information on WuXi PharmaTech's materials characterization capabilities, please seehttp://www.wuxiapptec.com/meddev_materials_characterization.html/.
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Associate Director of Corporate Communications